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Abstract Elderly patients generally experience less
favorable outcomes and higher mortality after acute stroke
than younger patients. The aim of this study was to analyze
the influence of age on outcome and safety after endo-
vascular therapy in a large cohort of patients aged between
20 and 90 years. We prospectively acquired data of 1,000
stroke patients treated with endovascular therapy at a single
center. Logistic regression analysis was performed to
determine predictors of outcome and linear regression
analysis to evaluate the association of age and outcome
after 3 months. Younger age was an independent predictor
of favorable outcome (OR 0.954, p \ 0.001) and survival
(OR 0.947, p \ 0.001) in multivariate regression analysis.
There was a linear relationship between age and outcome.
Ever increase in 26 years of age was associated with an
increase in the modified Rankin Scale of 1 point
(p \ 0.001). However, increasing age was not a risk factor
for symptomatic (p = 0.086) or asymptomatic (p = 0.674)
intracerebral hemorrhage and did not influence recanali-
zation success (p = 0.674). Advancing age was associated
with a decline of favorable outcomes and survival after
endovascular therapy. This decline was linear from age 20
to 90 years, but was not related to lower recanalization
rates or higher bleeding risk in the elderly. The efficacy of
endovascular stroke therapy seems to be preserved also in
the elderly and other factors than efficacy of endovascular
therapy such as decreased plasticity are likely to explain
the worse outcome with advancing age.
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Introduction
Outcome after stroke is known to be less favorable in
elderly patients and mortality is increased compared to
younger ones [1–3]. Intravenous thrombolysis (IVT)
improves outcome and can be performed safely both in
younger and elderly patients but outcome in the elderly is
still less favorable than in younger patients [4–13].
Endovascular treatment trials such as and IMS 1, IMS 2,
and SYNTHESIS excluded patients older than 80 years
[14–16]. Only PROACT II, IMS 3 and MR Rescue inclu-
ded patients up to 85 years [17–19]. In a previous analysis,
we found similar rates of recanalization and symptomatic
intracerebral hemorrhages (ICH) after endovascular treat-
ment in our patients older than 80 years compared to our
younger patients but outcomes were generally less favor-
able and survival decreased [20]. These results concur with
the results of other studies on endovascular-treated patients
[21–24].
Almost all studies that addressed the outcome of elderly
people after acute stroke dichotomized patients according
to patients’ age with a cutoff of 80 years. This categorical
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handling of age leads to the impression that 80 years is a
critical age, after which outcome becomes worse. How-
ever, age seems to be an independent predictor of outcome
also in patients younger than 80 years [25].
The aim of this study was to analyze the influence of age
on outcome and safety after endovascular therapy for acute
stroke is in a large cohort of patients aged between 20 and
90 years.
Patients and methods
Patients
From May 1992 to June 2012, we treated 1,000 patients
aged between 20 and 90 years with endovascular therapy.
Some aspects of these patients have been reported previ-
ously [20, 26, 27].
A neurologist examined all patients immediately after
admission to the emergency room and the neurologic def-
icit was scored using the National Institutes of Health
Stroke Scale (NIHSS). Demographic and clinical data were
recorded [age, gender, time of symptom onset, coronary
artery disease, atrial fibrillation, hypertension, diabetes,
current smoking, hypercholesterolemia according to his-
tory or current lipid values, history of transient ischemic
attack (TIA) or ischemic stroke]. Afterwards, patients
underwent computed tomography (CT) or magnetic reso-
nance imaging (MRI). Endovascular therapy was per-
formed with the consent of the patient or his family
immediately after CT or MRI if: (1) diagnosis of ischemic
stroke was established; (2) baseline NIHSS score was C4
points or isolated aphasia or hemianopia was present; (3)
hemorrhage on cranial CT or MRI was excluded; (4) vessel
occlusion correlated with the neurological deficit; and (5)
no individual clinical or premorbid conditions or laboratory
findings advised against thrombolysis. Digital subtraction
angiography (DSA) was performed via a transfemoral
approach using a biplane, high-resolution angiography
system (1992–2006: CAS 2006, Toshiba, since 2007:
Axiom Artis Zee, Siemens, Erlangen, Germany). In gen-
eral, four vessel cerebral angiography was performed.
Collaterals were classified as previously reported [25]. The
interventional neuroradiologists decided jointly with the
neurologist on the use of urokinase, mechanical interven-
tion [mainly aspiration and stent retriever since 2009;
Penumbra and Merci devices have rarely been used
(n \ 10) and fragmentation of the thrombus was avoided
whenever possible] or both as recanalization techniques. At
the end of the intervention, recanalization was classified
according to thrombolysis in myocardial infarction (TIMI)
grades.
A CT or MRI scan was obtained 24–72 h after treatment
or in any case of clinical deterioration. Symptomatic
(sICH) and asymptomatic intracranial bleedings (aICH)
were graded according to the PROACT II Study [28].
Clinical outcome was assessed 3 months after the stroke
using the modified Rankin Scale (mRS).
The study was performed according to the ethical
guidelines of the Canton of Bern and with corresponding
permission.
Statistical analysis
Statistical analysis was performed using SPSS 21 (SPSS
Inc., Chicago, IL, USA). Categorical variables were
Table 1 Baseline characteristics and outcome of 1,000 patients after endovascular treatment
20–29 years 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years 80–89 years
n 17 28 99 171 259 298 128
Female sex 9/17 (52.9) 17/28 (60.7) 51/99 (51.5) 52/171
(30.4)
100/259
(38.6)
141/298
(47.3)
77/128
(60.2)
NIHSS, median (range) 13 (5–31) 15 (0–36) 16 (3–36) 15 (2–36) 15 (0–36) 15 (2–36) 17 (2–36)
Time to recanalization (min), median
(range)
240
(135–472)
292
(15–971)
270
(80–705)
255
(45–943)
271
(18–1,210)
269
(16–1,472)
260
(77–1,440)
TIMI 2-3 recanalization 13/16 (81.3) 22/28 (78.6) 76/99 (76.8) 126/170
(74.1)
193/256
(75.4)
210/296
(70.9)
93/126
(73.8)
Symptomatic ICH 0 0 3/99 (3) 9/171 (5.3) 16/258 (6.2) 24/297 (8.1) 9/126 (7.1)
Asymptomatic ICH 2/17 (11.8) 1/28(3.6) 13/99 (13.1) 34/17 (19.9) 44/258
(17.1)
59/296
(19.9)
21/126
(16.7)
mRS 0–2 11/17 (64.7) 17/28 (60.7) 57/99 (57.6) 92/169
(54.4)
120/258
(46.5)
114/296
(38.5)
26/128
(20.3)
Survival 17/17 (100) 26/28 (92.9) 87/99 (87.9) 144/169
(85.1)
197/258
(76.4)
214/296
(72.3)
77/128
(60.2)
N (%) if not indicated otherwise
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compared with v2 and Fisher’s exact test as appropriate
and continuous variables with Mann–Whitney test. Out-
come was dichotomized into favorable (mRS 0–2) and
poor clinical outcome (mRS 3–6) and recanalization as
seen on DSA into good (TIMI grades 2–3) and poor
recanalization (TIMI grades 0–1). Forward stepwise
logistic regression including all variables with p \ 0.2 in
univariate analysis (age, gender, time to thrombolysis,
NIHSS score on admission, atrial fibrillation, vessel dis-
section, diabetes, hypertension, hypercholesterolemia,
coronary artery disease, previous stroke or TIA, smoking,
family history of stroke, occlusion type, degree of
collaterals, recanalization after IAT, dose of urokinase)
was used to determine the predictors of clinical outcome,
survival, recanalization and bleeding complications. A
p value \0.05 was considered significant. Linear regres-
sion analysis was used to analyze the relation between
age and mRS.
Results
Baseline characteristics and outcome of the 1,000 study
patients are given in Tables 1 and 2.
Table 2 Distribution of location of vessel occlusion, (%)
20–29 years 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years 80–89 years
ICA 23.5 17.9 34.3 25.1 30.1 20.1 20.3
MCA 58.8 57.1 43.4 58.5 53.7 63.8 67.2
BA 17.6 21.4 20.2 14 12.8 14.1 12.5
ACA 0 0 1 0.6 1.9 0 0
PCA 0 3.6 1 1.8 1.5 2 0
Fig. 1 Percentage of favorable
outcome (mRS 0–2) and
survival after 3 months for each
life decade of 1,000 patients
after endovascular treatment
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Advancing age was an independent predictor of unfa-
vorable outcome in multivariable regression analysis
(p \ 0.001, OR 0.954; other factors: NIHSS p \ 0.001,
OR 0.870; recanalization p \ 0.001, OR 3.716; diabetes
mellitus p \ 0.001, OR 0.383; hypercholesterolemia
p = 0.007, OR 1.586; collaterals p = 0.003, OR 1.438;
time to treatment p = 0.016, OR 0.998; location of vessel
occlusion p \ 0.001). Advancing age was also an inde-
pendent predictor of mortality (p \ 0.001, OR 0.947; other
factors: NIHSS p \ 0.001, OR 0.928; recanalization
p = 0.001, OR 1.906; diabetes mellitus p = 0.014, OR
0.568; hypercholesterolemia p = 0.039, OR 1.462; collat-
erals p \ 0.001, OR 1.878; location of vessel occlusion
p \ 0.001). There was a linear relationship between age
and outcome. When outcome was assessed with the mod-
ified Rankin Scale the score increased by one point per
26 years age increase (p \ 0.001) (Figs. 1, 2).
In multivariable regression analysis age did not predict
symptomatic ICH (predicting factor: collaterals p \ 0.001,
OR 0.432; age p = 0.086) or asymptomatic ICH (predict-
ing factors: atrial fibrillation p = 0.001, OR 1.856; base-
line NIHSS p = 0.010, OR 1.036; age p = 0.674). For
a
b
Fig. 2 a Mean modified Rankin
Scale after 3 months for each
life decade. b Distribution of
modified Rankin Scale after
3 months for each life decade
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TIMI 2–3 recanalization, we found the location of vessel
occlusion (p = 0.010) and the quality of collaterals
(p = 0.026, OR 1.276) as independent predictors, but not
age (p = 0.674).
Discussion
The chances for favorable outcome after acute stroke and
endovascular stroke therapy decline continuously with
advancing age from 20 to 90 years in a linear manner. This
is the main finding of our study. The mean modified Rankin
Score 3 months after the stroke increases by 1 point every
26 years of age increase; however, this age-related decline
of favorable outcome is not related to lower recanalization
rates or higher bleeding risk in the elderly.
Since stroke incidence is increasing with advancing age
and since life expectancy is growing in many societies, the
treatment of elderly stroke patients is becoming a major
issue in health care. There is growing evidence that IVT
can be performed safely and effectively in elderly stroke
patients, though the large intravenous and endovascular
therapy trials included only patients up to 80 or 85 years
old (NINDS; ECASS, PROACT, IMS 1 ? 2) [4–13].
Nevertheless, outcome in the older stroke patients seems to
be less favorable than in the younger.
In a previous study we showed that endovascular ther-
apy in 43 patients aged older than 80 years was as safe as
in 576 younger patients but clinical outcome was worse
[20]. These results concur with other endovascular therapy
studies that found worse outcome but not an increased risk
for ICH in patients older than 80 years [21–24].
All endovascular treatment trials and most trials on IVT
analyzed the influence of age in acute stroke therapy by
dichotomizing patients with a cutoff value of 80 years.
This categorical handling of age leads to the false
impression that 80 years is a critical age, after which out-
come becomes worse.
As expected, age was an independent predictor of out-
come and survival in the present analysis of 1,000 stroke
patients who received endovascular treatment. Moreover,
the chances of favorable outcome declined not only
between the categories older and younger than 80 years,
there was a linear relationship between outcome after
3 months and age from 20 to 90 years (p \ 0.001; Figs. 1,
2). The average mRS after 3 months increased by 1 point
mRS every 26 years advancing age.
The age dependent decline of outcome was not the result
of decreasing recanalization success or higher rates of
bleeding complications (there was only a trend for higher
rates). This indicates that endovascular stroke therapy in
the elderly is as effective as in young patients and that
other factors such as less cerebral reserve capacity
contribute to the worse outcome with advancing age.
Similarly, a large IVT trial found a similar treatment effect
of IVT in patients older and younger than 80 years (NNT
8.5 vs. 8.2), and in the IST-3 trial IVT showed even a
greater benefit in patients older than 80 years than in
younger patients [5, 29]. From these findings of the IVT
treatment effect and our data on endovascular therapy, we
conclude that advanced age should not be used to generally
advise against IVT or endovascular treatment in acute
stroke. The efficacy of endovascular treatment is preserved
even above the age of 80 years and an upper age limit for
its use does not seem to be justified.
Our study has several limitations. One of two major lim-
itations is the type of analysis. The analysis was performed
retrospectively on data that had been collected prospectively
and continuously and included all consecutive patients
treated at our stroke center. The other main limitation is the
selection of patients. Almost all patients underwent multi-
modal MR or CT imaging before treatment decisions were
made. Therefore, it is likely that we had selected patients
with better chances for good outcomes for endovascular
treatment, but this selection bias for treatment decisions
applies both for younger and older patients. Due to the lack of
an untreated control group, we can only state on the recan-
alization efficacy of endovascular treatment and cannot state
whether these patients benefit from therapy. In addition, the
trend for more bleeding complications in the elderly might be
non-significant due to the overall low rates of ICH.
In conclusion, the chances for favorable outcome after
endovascular therapy decreased continuously in a linear
manner from age 20 to 90 years. However, this decline was
not related to lower recanalization rates or higher bleeding
risk in the elderly. The recanalization efficacy of endo-
vascular stroke therapy seems to be preserved also in the
elderly and advanced age should not generally advise
against the use of endovascular treatment in acute stroke.
Future prospective randomized trials should not use an
upper age limit for study patients to evaluate safety and
efficacy of endovascular stroke treatment.
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